BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.

被引：0

作者：

Noguchi, Shinzaburo

Masuda, Norikazu

Ito, Yoshinori

Iwata, Hiroji

Mukai, Hirofumi

Horiguchi, Jun

Tokuda, Yutaka

Kuroi, Katsumasa

Iwase, Hirotaka

Inaji, Hideo

Ohsumi, Shozo

Piccart-Gebhart, Martine J.

Hortobagyi, Gabriel N.

Rugo, Hope S.

Gnant, Michael

Campone, Mario

Sahmoud, Tarek

Pritchard, Kathleen I.

Burris, Howard A.

Baselga, Jose

机构：

[1] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan

[2] Osaka Natl Hosp, Osaka, Japan

[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Breast Oncol Ctr, Tokyo, Japan

[4] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan

[5] East Hosp, Natl Canc Ctr, Kashiwa, Chiba, Japan

[6] Gunma Univ Hosp, Maebashi, Gunma, Japan

[7] Tokai Univ Hosp, Isehara, Kanagawa, Japan

[8] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Tokyo, Japan

[9] Kumamoto Univ, Dept Breast & Endocrine Surg, Kumamoto, Japan

[10] Med Ctr Canc & Cardiovasc Dis, Osaka, Japan

[11] NHO Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan

[12] Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium

[13] Univ Texas Houston, Houston, TX USA

[14] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[15] Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria

[16] Ctr Rech Cancerol, Inst Cancerol Ouest Rene Gauducheau, St Herblain, France

[17] Novartis Pharmaceut, E Hanover, NJ USA

[18] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[19] Sarah Cannon Res Inst, Nashville, TN USA

[20] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[21] Harvard Univ, Sch Med, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

540

引用

页数：1

共 50 条

[1] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
Noguchi, Shinzaburo
Masuda, Norikazu
Iwata, Hiroji
Mukai, Hirofumi
Horiguchi, Jun
Puttawibul, Puttisak
Srimuninnimit, Vichien
Tokuda, Yutaka
Kuroi, Katsumasa
Iwase, Hirotaka
Inaji, Hideo
Ohsumi, Shozo
Noh, Woo-Chul
Nakayama, Takahiro
Ohno, Shinji
Rai, Yoshiaki
Park, Byeong-Woo
Panneerselvam, Ashok
El-Hashimy, Mona
Taran, Tetiana
Sahmoud, Tarek
Ito, Yoshinori
[J]. BREAST CANCER, 2014, 21 (06) : 703 - 714
[2] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
Shinzaburo Noguchi
Norikazu Masuda
Hiroji Iwata
Hirofumi Mukai
Jun Horiguchi
Puttisak Puttawibul
Vichien Srimuninnimit
Yutaka Tokuda
Katsumasa Kuroi
Hirotaka Iwase
Hideo Inaji
Shozo Ohsumi
Woo-Chul Noh
Takahiro Nakayama
Shinji Ohno
Yoshiaki Rai
Byeong-Woo Park
Ashok Panneerselvam
Mona El-Hashimy
Tetiana Taran
Tarek Sahmoud
Yoshinori Ito
[J]. Breast Cancer, 2014, 21 : 703 - 714
[3] Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2
Pritchard, Kathleen I.
Burris, Howard A., III
Ito, Yoshinori
Rugo, Hope S.
Dakhil, Shaker
Hortobagyi, Gabriel N.
Campone, Mario
Csoszi, Tibor
Baselga, Jose
Puttawibul, Puttisak
Piccart, Martine
Heng, Daniel
Noguchi, Shinzaburo
Srimuninnimit, Vichien
Bourgeois, Hugues
Gonzalez Martin, Antonio
Osborne, Karen
Panneerselvam, Ashok
Taran, Tetiana
Sahmoud, Tarek
Gnant, Michael
[J]. CLINICAL BREAST CANCER, 2013, 13 (06) : 421 - U113
[4] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
Beaver, Julia A.
Park, Ben H.
[J]. FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
[5] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit, Mariya
Mun, Sophia
Soulos, Pamela
Adelson, Kerin
Pusztai, Lajos
Mougalian, Sarah
[J]. BREAST CANCER RESEARCH, 2021, 23 (01)
[6] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Mariya Rozenblit
Sophia Mun
Pamela Soulos
Kerin Adelson
Lajos Pusztai
Sarah Mougalian
[J]. Breast Cancer Research, 23
[7] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
Ottestad, Lars
Fronth, Line
Rajendiran, Sajitha
Aksnes, Liv Hege
Eikesdal, Hans Petter
Blix, Egil Store
Ewertz, Marianne
[J]. ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
[8] Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2
Prat, Aleix
Christoph Brase, Jan
Cheng, Yuan
Nuciforo, Paolo
Pare, Laia
Pascual, Tomas
Martinez, Debora
Galvan, Patricia
Vidal, Maria
Adamo, Barbara
Hortobagyi, Gabriel N.
Baselga, Jose
Ciruelos, Eva
[J]. ONCOLOGIST, 2019, 24 (07): : 893 - 900
[9] Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.
Niu, Nan
Cao, Shuo
Chen, Guanglei
Xue, Jinqi
Zhang, Yu
Xu, Yongqing
Yin, Jianqiao
Liu, Chao
Jiang, Xiaofan
Tang, Meiyue
Xu, Qianshi
Jia, Mingxuan
Zhang, Xu
Zhang, Zhenyong
Li, Huajun
Li, Ailin
Liu, Caigang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Sohita Dhillon
[J]. Drugs, 2013, 73 : 475 - 485

← 1 2 3 4 5 →